focus -WSS

focus

author：knowledge 2025-09-06 03:50:55 - browse：1

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Timeline: Key moments in fight for gay rights

WSS

340B reform proposal comes out of Senate working group

AstraZeneca stays mum on Medicare drug pricing negotiations

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Eli Lilly’s Mounjaro succeeds in second weight

Can medical device makers keep up in the race to treat obesity?

hotspot

focus

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Senate panel passes drug pricing bills, but drops one PBM reform

Affirmative action in medical school literally saved lives

Timeline: Key moments in fight for gay rights

Heart attack and stroke risk calculators need revising

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Wildfire smoke exposes gaps in outdoor worker protections

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Wildfire smoke exposes gaps in outdoor worker protections

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

hotspot

Novo pauses ads for weight loss drug Wegovy amid demand

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Cano Health’s bankruptcy is a warning for Medicare Advantage

Top private equity targets in 2023: cardiology, clinical trials, lasers

Patients, doctors are clashing about side effects of hormonal birth control

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

explore

entertainment

hotspot

focus